GILD · Gilead Sciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.96B | - | $7.77B | $7.08B | $6.67B | - | $7.54B | $6.95B | $6.69B | - |
| Cost of Revenue | $1.45B | - | $1.57B | $1.50B | $1.54B | - | $1.57B | $1.54B | $1.55B | - |
| Gross Profit | $5.51B | - | $6.20B | $5.58B | $5.13B | - | $5.97B | $5.41B | $5.13B | - |
| R&D | $1.37B | - | $1.35B | $1.49B | $1.38B | - | $1.40B | $1.35B | $1.52B | - |
| SG&A | $1.45B | - | $1.36B | $1.36B | $1.26B | - | $1.43B | $1.38B | $1.38B | - |
| Total Operating Expenses | $4.37B | - | $4.44B | $4.61B | $4.43B | - | $6.66B | $4.31B | $11.01B | - |
| D&A | $93.00M | - | $90.00M | $98.00M | $97.00M | - | - | - | $94.00M | - |
| Operating Income | $2.59B | - | $3.33B | $2.47B | $2.24B | - | $888.00M | $2.64B | ($4.32B) | - |
| Interest Expense | $240.00M | - | $256.00M | $254.00M | $254.00M | - | $232.00M | $230.00M | $254.00M | - |
| Income Tax | $559.00M | - | $589.00M | $468.00M | $334.00M | - | ($297.00M) | $438.00M | ($315.00M) | - |
| Net Income | $2.02B | - | $3.05B | $1.96B | $1.31B | - | $1.25B | $1.61B | ($4.17B) | - |
| EPS - Basic | $1.63 | - | $2.46 | $1.57 | $1.06 | - | $1.00 | $1.29 | ($3.34) | - |
| EPS - Diluted | $1.61 | - | $2.43 | $1.56 | $1.04 | - | $1.00 | $1.29 | ($3.34) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.63B | $7.56B | $7.33B | $5.14B | $7.93B | $9.99B | $5.04B | $2.77B | $4.72B | $6.08B |
| Accounts Receivable | $4.74B | $4.91B | $5.09B | $4.78B | $4.39B | $4.42B | $4.59B | $4.66B | $4.67B | $4.66B |
| Inventory | $1.91B | $1.77B | $1.78B | $1.82B | $1.76B | $1.71B | $1.87B | $2.03B | $1.85B | $1.79B |
| Accounts Payable | $645.00M | $715.00M | $808.00M | $582.00M | $737.00M | $833.00M | $903.00M | $537.00M | $622.00M | $550.00M |
| Current Assets | $18.64B | $18.34B | $17.87B | $14.72B | $16.90B | $19.17B | $14.78B | $12.32B | $14.04B | $16.09B |
| Total Assets | $56.28B | $59.02B | $58.53B | $55.72B | $56.43B | $58.99B | $54.52B | $53.58B | $56.29B | $62.13B |
| Current Liabilities | $9.48B | $11.81B | $12.30B | $11.19B | $12.34B | $12.00B | $11.72B | $10.78B | $13.02B | $11.28B |
| Long-term Debt | $20.86B | $22.13B | $22.14B | $22.14B | $22.15B | $24.90B | $21.44B | $21.54B | $21.53B | $23.19B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $23.52B | $22.70B | $21.54B | $19.67B | $19.16B | $19.33B | $18.48B | $18.28B | $17.54B | $22.83B |
| Retained Earnings | $14.13B | $13.73B | $12.82B | $11.32B | $10.93B | $11.50B | $11.07B | $11.16B | $10.66B | $16.30B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.54B | - | - | - | $1.76B | - | - | - | $2.22B | - |
| Investing Cash Flow | $1.77B | - | - | - | ($415.00M) | - | - | - | ($2.21B) | - |
| Financing Cash Flow | ($4.24B) | - | - | - | ($3.43B) | - | - | - | ($1.36B) | - |
| CapEx | $117.00M | - | - | - | $104.00M | - | - | - | $105.00M | - |
| Free Cash Flow | $2.43B | - | - | - | $1.65B | - | - | - | $2.11B | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 79.2% | - | 79.8% | 78.8% | 76.9% | - | 79.1% | 77.8% | 76.8% | - |
| Operating margin | 37.2% | - | 42.8% | 34.9% | 33.6% | - | 11.8% | 38.0% | -64.6% | - |
| EBITDA margin | 38.5% | - | 44.0% | 36.3% | 35.0% | - | - | - | -63.2% | - |
| Net margin | 29.0% | - | 39.3% | 27.7% | 19.7% | - | 16.6% | 23.2% | -62.4% | - |
| Free cash flow margin | 34.9% | - | - | - | 24.8% | - | - | - | 31.6% | - |
| FCF / Net income | 1.20 | - | - | - | 1.26 | - | - | - | -0.51 | - |
| R&D / Revenue | 19.7% | - | 17.3% | 21.1% | 20.7% | - | 18.5% | 19.4% | 22.7% | - |
| SG&A / Revenue | 20.8% | - | 17.5% | 19.3% | 18.9% | - | 19.0% | 19.8% | 20.6% | - |
| Effective tax rate | 21.7% | - | 16.2% | 19.3% | 20.3% | - | -31.1% | 21.3% | - | - |
| Return on assets | 3.6% | - | 5.2% | 3.5% | 2.3% | - | 2.3% | 3.0% | -7.4% | - |
| Return on equity | 8.6% | - | 14.2% | 10.0% | 6.9% | - | 6.8% | 8.8% | -23.8% | - |
| Return on invested capital | 4.6% | - | 6.4% | 4.8% | 4.3% | - | 2.2% | 5.2% | -8.7% | - |
| Liquidity | ||||||||||
| Current ratio | 1.97 | 1.55 | 1.45 | 1.32 | 1.37 | 1.60 | 1.26 | 1.14 | 1.08 | 1.43 |
| Quick ratio | 1.77 | 1.40 | 1.31 | 1.15 | 1.23 | 1.45 | 1.10 | 0.95 | 0.94 | 1.27 |
| Cash ratio | 0.80 | 0.64 | 0.60 | 0.46 | 0.64 | 0.83 | 0.43 | 0.26 | 0.36 | 0.54 |
| Leverage | ||||||||||
| Debt / Equity | 0.89 | 0.97 | 1.03 | 1.13 | 1.16 | 1.29 | 1.16 | 1.18 | 1.23 | 1.02 |
| Debt / Assets | 0.37 | 0.37 | 0.38 | 0.40 | 0.39 | 0.42 | 0.39 | 0.40 | 0.38 | 0.37 |
| Debt / EBITDA | 7.79 | - | 6.48 | 8.61 | 9.49 | - | - | - | - | - |
| Interest coverage | 10.8x | - | 13.0x | 9.7x | 8.8x | - | 3.8x | 11.5x | -17.0x | - |
| Equity multiplier | 2.39 | 2.60 | 2.72 | 2.83 | 2.95 | 3.05 | 2.95 | 2.93 | 3.21 | 2.72 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.12 | - | 0.13 | 0.13 | 0.12 | - | 0.14 | 0.13 | 0.12 | - |
| Inventory turnover | 0.75 | - | 0.88 | 0.82 | 0.88 | - | 0.84 | 0.76 | 0.84 | - |
| Days sales outstanding | 249d | - | 239d | 246d | 240d | - | 222d | 245d | 255d | - |
| Days inventory outstanding | 483d | - | 415d | 444d | 417d | - | 433d | 479d | 436d | - |
| Days payable outstanding | 163d | - | 188d | 142d | 175d | - | 209d | 127d | 146d | - |
| Cash conversion cycle | 569d | - | 467d | 549d | 482d | - | 446d | 597d | 544d | - |
| Valuation | ||||||||||
| P / E | 86.6x | - | 45.7x | 71.1x | 107.7x | - | 83.8x | 53.2x | - | - |
| P / B | 7.4x | - | 6.5x | 7.1x | 7.4x | - | 5.7x | 4.7x | 5.2x | - |
| P / S | 25.1x | - | 17.9x | 19.6x | 21.2x | - | 13.9x | 12.3x | 13.7x | - |
| EV / EBITDA | 70.2x | - | 45.1x | 60.7x | 66.5x | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 4.4% | - | 3.0% | 1.8% | -0.3% | - | 7.0% | 5.4% | 5.3% | - |
| Revenue CAGR (3y) | 3.1% | - | 3.3% | 4.2% | 0.4% | - | 4.7% | 3.8% | 6.4% | - |
| Revenue CAGR (5y) | 4.6% | - | 3.4% | 6.6% | 3.7% | - | 6.1% | 4.1% | 4.8% | - |
| Gross profit growth (YoY) | 7.6% | - | 3.8% | 3.2% | -0.1% | - | 8.8% | 4.9% | 3.7% | - |
| Operating income growth (YoY) | 15.6% | - | 274.7% | -6.4% | - | - | -66.1% | 58.8% | - | - |
| Net income growth (YoY) | 53.7% | - | 143.6% | 21.4% | - | - | -42.5% | 54.4% | - | - |
| EPS growth (YoY) | 54.8% | - | 143.0% | 20.9% | - | - | -42.2% | 55.4% | - | - |
| EPS CAGR (3y) | 26.3% | - | 19.6% | 19.7% | 273.3% | - | -21.3% | 2.2% | - | - |
| EPS CAGR (5y) | 3.3% | - | 53.0% | - | -3.1% | - | - | -2.6% | - | - |
| FCF growth (YoY) | 46.8% | - | - | - | -21.8% | - | - | - | 29.3% | - |
| FCF CAGR (5y) | -0.1% | - | - | - | 5.5% | - | - | - | 11.9% | - |
| Book value growth (YoY) | 22.7% | 17.4% | 16.6% | 7.6% | 9.3% | -15.3% | -17.2% | -13.6% | -16.5% | 7.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$71.35B totalProduct$28.91B · 40.5%
HIVProduct Sales$16.90B · 23.7%
HIVProducts Biktarvy$11.47B · 16.1%
HIVProducts Descovy$2.56B · 3.6%
Oncology Product$1.63B · 2.3%
Liver Disease$1.62B · 2.3%
HIVProducts Genvoya$1.28B · 1.8%
HIVProducts Odefsey$881.00M · 1.2%
Trodelvy$877.00M · 1.2%
Cell Therapy Products Total Cell Therapy Product Sales$748.00M · 1.0%
Liver Disease Products Sofosbuvir Velpatasvir$636.00M · 0.9%
Other Products Yescarta$595.00M · 0.8%
Royalty Contract And Other$527.00M · 0.7%
Liver Disease Products Vemlidy$507.00M · 0.7%
Liver Disease Products Other Liver Disease$476.00M · 0.7%
Veklury$470.00M · 0.7%
HIVProducts Symtuza Revenue Share$363.00M · 0.5%
HIVProducts Other HIV$352.00M · 0.5%
Other Products Total Other Product Sales$197.00M · 0.3%
Other Products Other$177.00M · 0.2%
Cell Therapy Products Tecartus$153.00M · 0.2%
Other Products Am Bisome$20.00M · 0.0%
Geographic
$29.44B totalUS$20.88B · 70.9%
Europe$5.06B · 17.2%
Rest Of World$3.50B · 11.9%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing GILEAD SCIENCES against the 5 most active filers in the same SIC group.
Dividends
$3.19/share trailing 12 months · +2.9% YoY
| Ex-date | Per share |
|---|---|
| Mar 13, 2026 | $0.8200 |
| Dec 15, 2025 | $0.7900 |
| Sep 15, 2025 | $0.7900 |
| Jun 13, 2025 | $0.7900 |
| Mar 14, 2025 | $0.7900 |
| Dec 13, 2024 | $0.7700 |
| Sep 13, 2024 | $0.7700 |
| Jun 14, 2024 | $0.7700 |
| Mar 14, 2024 | $0.7700 |
| Dec 14, 2023 | $0.7500 |
| Sep 14, 2023 | $0.7500 |
| Jun 14, 2023 | $0.7500 |
| Mar 14, 2023 | $0.7500 |
| Dec 14, 2022 | $0.7300 |
| Sep 14, 2022 | $0.7300 |
| Jun 14, 2022 | $0.7300 |
| Mar 14, 2022 | $0.7300 |
| Dec 14, 2021 | $0.7100 |
| Sep 14, 2021 | $0.7100 |
| Jun 14, 2021 | $0.7100 |
| Mar 12, 2021 | $0.7100 |
| Dec 14, 2020 | $0.6800 |
| Sep 14, 2020 | $0.6800 |
| Jun 11, 2020 | $0.6800 |